Therapeutic drug monitoring in human immunodeficiency virus/acquired immunodeficiency syndrome: Quo vadis?

Archives of Pathology and Laboratory Medicine

Volumn 127, Issue 1, 2003, Pages 102-104

  Soldin, Offie Porat ^a   Elin, Ronald J ^b   Soldin, Steven J ^c,d,e  

^a Epidemiology and Occupational Health Inc   (United States)

^b University of Louisville School of Medicine   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MASS SPECTROMETRY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; STEADY STATE; TREATMENT OUTCOME; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0037280572     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. The economics of HIV in Africa [editorial]. Lancet. 2002:360;1.
2. UNAIDS. AIDS epidemic update: December 2001. Available at: http:// www.unaids.org/epidemic_update/report_dec01/index.html. Accessed June 2002.
3. Centers for Disease Control and Prevention, Divisions of HIV/AIDS Prevention. Human immunodeficiency virus type 2. Available at: http://www.cdc.gov/hiv/pubs/facts/hiv2.htm. Accessed June 2002.
4. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA. 2000;283:2653-2654.
5. Office of Communications and Public Liaison, National Institute of Allergy and Infectious Diseases. Fact Sheet. Bethesda, Md: National Institutes of Health; May 2001.
6. The National Institute of Allergy and Infectious Diseases (March 1999). Available at: http://www.niaid.nih.gov/factsheets/hiv inf.htm. Accessed June 2002.
7. Centers for Disease Control and Prevention. HIV/AIDS surveillance report. 1999;11:1-44.
8. Dasgupta A, Okhuysen PC. Pharmacokinetic and other drug interactions in patients with AIDS. Ther Drug Monit. 2001;23:591-605.
9. van Heeswick RPG. Critical issues in therapeutic drug monitoring of antiretroviral drugs. Ther Drug Monit. 2002;24:323-331.
10. Soldin OP, Soldin SJ. Therapeutic drug monitoring in pediatrics. Ther Drug Monit. 2002;24:1-8.
11. Gerber JG. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection. Clin Infect Dis. 2000;30(suppl 2):S123-S129.
12. Back DJ, Khoo SH, Gibbons SE, et al. Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection. Ther Drug Monit. 2000;22:122-126.
13. Merry C. Therapeutic drug monitoring of antiretroviral drugs. Northwestern Univ Rep HIV/AIDS. 2000;4:1-8.
14. van Heeswick RPG, Veidkamp AI, Mulder JW, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS. 2000;14:F77-F82.
15. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradept study. AIDS. 2000;14:1333-1339.
16. Burger D, Hugen P, Droste J, et al. Therapeutic drug monitoring (TDM) of nelfinavir (NFV) and indinavir (IDV) in treatment-naïve patients improves therapeutic outcome after 1 year: results from ATHENA. In: Abstracts of the First IAS Conference on HIV Pathogenesis and Treatment; 2001; Buenos Aires, Argentina. Abstract 30.
17. Lebergeber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet. 1999;353:863-868.
18. Erb P, Battegay M, Zimmerli W, et al. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort: Swiss Cohort Study. Arch Intern Med. 2000;160:1134-1140.
19. Junghans C, Low N, Chan P, et al. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS. 1999;13:2547-2554.
20. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk of virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-87.
21. Veldkamp AI, Weverling GJ, Lange JM, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS. 2001;15:1089-1095.
22. Hoetelmans RMW, Reijers MHE, Weverling GJ, et al. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS. 1998;12:F111-F115.
23. Gatti G, Di Biagio A, Casazza R, et al. The relationship between ritonavir plasma levels and side effects: implications for therapeutic drug monitoring. AIDS. 1999;13:2083-2089.
24. Sadler BM, Gillotin C, Lou C, et al. Pharmacokinetic and pharmacodynamic study of the immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agents Chemother. 2001;45:30-37.
25. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-75.
26. Fletcher CV, Anderson PL, Kakuda TN, et al. Concentration controlled compared with conventional antiretroviral therapy for HIV infection. AIDS. 2002; 16:551-560.
27. Anderson PL, Fletcher CV. Clinical pharmacologic considerations for HIV-1 protease inhibitors. Curr Infect Dis Rep. 2001;3:381-387.
28. Fletcher CV, Balfour HH Jr. Variability in zidovudine serum concentrations. Pharmacotherapy. 1996;16:1154-1158.
29. Barry MG, Merry C, Lloyd J, et al. Variability in trough plasma saquinavir concentrations in HIV case for therapeutic drug monitoring. Br J Clin Pharmacol. 1998;45:501-502.
30. Moyer TP, Temesgen Z, Enger R, et al. Drug monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study. Clin Chem. 1999;45:1465-1476.
31. Titier K, Lagrange F, Pehourcq F, et al. High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma. Ther Drug Monit. 2002;24:417-424.
32. Villani P, Feroggio M, Gianelli L, et al. Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography-mass spectrometry assay. Ther Drug Monit. 2002;24:380-388.
33. Volosov A, Alexander C, Ting L, Soldin SJ. Simple rapid method for quantification of antiretrovirals by liquid chromatography-tandem mass-spectrometry. Clin Biochem. 2002;35:99-103.
34. Volosov A, Napoli KL, Soldin SJ. Simultaneous simple, and fast quantification of three major immunosuppressants by liquid chromatography-tandem mass-spectrometry. Clin Biochem. 2001;34:285-290.